← Back

Nexalin Technology Inc.

Nexalin Technology, Inc. is a medical device company that designs and develops neurostimulation products for treating mental health conditions in the United States and China. Its Generation 1 device uses bioelectronic medical technology to treat anxiety, insomnia, and depression without drugs or psychotherapy. The company also offers Generation 2 and Generation 3 headset devices for depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, chronic pain, Alzheimer's disease, and dementia. It is headquartered in Houston, Texas.

Country
Price · split & dividend adjusted
News & notes moving NXL
NXL

Nexalin Technology Announces 1-for-30 Reverse Stock Split

Nexalin Technology, Inc. announced that its board of directors has approved a 1-for-30 reverse stock split of its common stock to ensure continued compliance with the Nasdaq bid-price rule. The split will become effective on August 28, 2026, at 5:00 pm Eastern Time, and the company's shares are expected to begin trading on a split-adjusted basis on The Nasdaq Capital Market under the ticker symbol "NXL" on August 31, 2026. Every 30 shares of issued and outstanding common stock will be combined into one share, with the par value remaining unchanged at $0.001 per share. No fractional shares will be issued; stockholders entitled to a fractional share will receive a proportional cash payment. Continental Stock Transfer & Trust Co. will serve as the exchange agent, and stockholders holding shares in book-entry or street name will have their positions automatically adjusted.
GlobeNewswire·22dRead more →